Sutro Biopharma宣布1.1亿美元承销发行定价-动脉网

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

Sutro Biopharma 等信源发布 2026-02-10 07:00



可切换为仅中文







SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share.

南旧金山，加利福尼亚州，2026年2月10日（环球新闻社）——Sutro Biopharma, Inc.（Sutro或公司）（纳斯达克股票代码：STRO），一家处于临床阶段的肿瘤学公司，专注于位点特异性和新型抗体药物偶联物（ADCs）的开发，今日宣布了其普通股7,868,383股的承销发行定价，每股价格为13.98美元。

The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about February 11, 2026, subject to the satisfaction of customary closing conditions..

预计本次发行的总收益在扣除承销折扣、佣金和其他发行费用之前约为 1.1 亿美元。所有普通股股份均由 Sutro 提供。此次发行预计将在 2026 年 2 月 11 日或前后完成，但需满足惯例成交条件。

The offering includes participation from new and existing investors, including BVF Partners L.P., Samsara BioCapital, Coastlands Capital, Eventide Asset Management, Perceptive Advisors, RA Capital Management, ADAR1 Capital Management, Affinity Asset Advisors and Acuta Capital Partners.

此次发行包括新投资者和现有投资者的参与，其中包括BVF Partners L.P.、Samsara BioCapital、Coastlands Capital、Eventide Asset Management、Perceptive Advisors、RA Capital Management、ADAR1 Capital Management、Affinity Asset Advisors和Acuta Capital Partners。

Leerink Partners, TD Cowen and LifeSci Capital are acting as joint bookrunning managers for the proposed offering.

Leerink Partners、TD Cowen和LifeSci Capital担任此次拟议发行的联合账簿管理人。

Sutro intends to use the net proceeds of this offering, together with its existing cash, cash equivalents and marketable securities, primarily for general corporate purposes, which may include funding research, clinical and process development and manufacturing of its product candidates, increasing its working capital, acquisitions or investments in businesses, products or technologies that are complementary to the Company, capital expenditures and other general corporate purposes..

Sutro 打算将此次发行的净收益与其现有的现金、现金等价物和可出售证券一起使用，主要用于一般公司用途，可能包括为其产品候选者的研发、临床和工艺开发及制造提供资金、增加其营运资本、对与公司互补的企业、产品或技术进行收购或投资、资本支出以及其他一般公司用途。

The securities are being offered by Sutro pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the prospectus supplement and the accompanying prospectus relating to this offering, may also be obtained, when available, from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext.

这些证券正由Sutro根据之前提交并经美国证券交易委员会（SEC）宣布生效的S-3表格注册声明进行发售。与此发行相关的招股说明书补充文件及附带的招股说明书将提交给SEC。当可供获取时，有关此次发行的招股说明书补充文件和附带的招股说明书副本也可通过以下方式获得：Leerink Partners LLC，收件人：辛迪加部门，地址：马萨诸塞州波士顿州街53号40楼，邮编02109，电话：（800）808-7525，分机。

6105, or by email at .

6105，或通过电子邮件发送至。

syndicate@leerink.com

辛迪加@雷林克.康母

; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at

; TD证券（美国）有限责任公司，c/o Broadridge金融解决方案，地址：纽约州埃奇伍德长岛大道1155号，邮编11717，或通过电子邮件发送至

TDManualrequest@broadridge.com

; or LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at compliance@lifescicapital.com Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

；或LifeSci Capital LLC，地址：纽约州纽约市百老汇1700号40楼，邮编10019，或通过电子邮件联系compliance@lifescicapital.com。招股说明书补充文件和随附的招股说明书的电子副本也可在SEC网站http://www.sec.gov上查阅。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Sutro, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售或征求购买Sutro任何证券的要约，亦不得在任何州或司法管辖区出售这些证券，若在此类州或司法管辖区中，此类要约、征求或出售在根据其证券法进行注册或资格认证之前属于非法行为。

About Sutro Biopharma

关于Sutro Biopharma

Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types.

Sutro Biopharma, Inc. 正在推进一个下一代抗体药物偶联物 (ADC) 平台，该平台旨在提供单载荷和双载荷的 ADC，为癌症患者带来有意义的突破。通过全面优化抗体、连接子和载荷，Sutro 的无细胞平台生产的 ADC 旨在改善药物暴露、减少副作用，并扩大可治疗的肿瘤类型范围。

With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies..

凭借在双载荷ADC领域的独特能力，Sutro旨在克服治疗耐药性，并重新定义癌症治疗的可能性。公司单载荷和双载荷ADC的研发管线针对治疗选择有限且对改进疗法需求巨大的大型肿瘤市场。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements the Company makes regarding the satisfaction of customary closing conditions related to the offering and sale of securities, the Company’s ability to complete the offering, anticipated gross proceeds from the offering and expected use of proceeds; anticipated preclinical and clinical development activities, timing of announcements of clinical results, potential efficacy, safety and benefits of STRO-004, potential insights gained and benefits of the Phase 1 trial design; potential benefits of the Company’s other product candidates and platform, and potential market opportunities for the Company’s product candidates.

本新闻稿包含1995年《私人证券诉讼改革法案》“安全港”条款意义上的前瞻性陈述，包括但不限于公司关于与证券发行和销售相关的惯例交割条件的满足、公司完成发行的能力、发行的预期总收入和所得款项的预期用途、预期的临床前和临床开发活动、临床结果公告的时间、STRO-004的潜在疗效、安全性和益处、第一阶段试验设计可能带来的见解和益处、公司其他候选产品和平台的潜在优势以及公司候选产品的潜在市场机会的陈述。

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain.

所有非历史事实的陈述均可能被视为前瞻性陈述。尽管公司认为这些前瞻性陈述中反映的预期是合理的，但公司无法保证未来事件、结果、行动、活动水平、表现或成就，且生物技术开发和潜在监管批准的时间与结果本质上存在不确定性。

Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s expectation of market conditions and the satisfaction of customary closing conditions related to the offering, the Company’s ability to complete the offering and expected use of proceeds, the Company’s ability to advance its product candidates, the re.

前瞻性声明受到风险和不确定性的约束，可能导致公司的实际活动或结果与任何前瞻性声明中表达的内容显著不同，包括与公司对市场状况的预期、与发行相关的惯例交割条件的满足、公司完成发行及预期资金用途、公司推进其产品候选物的能力相关的风险和不确定性。

Investor Contact

投资者联系

Emily White

艾米丽·怀特

Sutro Biopharma

德罗生物制药

(650) 823-7681

ewhite@sutrobio.com

Media Contact

媒体联系人

Amy Bonanno